Regenxbio reports Q4 EPS ($1.38), consensus ($1.23)
The Fly

Regenxbio reports Q4 EPS ($1.38), consensus ($1.23)

Reports Q4 revenue $31.3M, consensus $37.45M. Cash, cash equivalents and marketable securities were $565.2M as of December 31, 2022, compared to $849.3M as of December 31, 2021. "REGENXBIO enters the year with a strong pipeline of AAV Therapeutics. One year ago, we introduced our ‘5x’25’ strategy and I remain confident that we will achieve this goal," said Kenneth T. Mills, President and CEO "Our lead candidate, RGX-314, is being developed in partnership with AbbVie for the treatment of wet AMD and diabetic retinopathy, which present opportunities to make an impact in eye care for millions of patients. In 2022, we made meaningful progress with our RGX-314 trial enrollment objectives and geographic expansion planning. We also established in-house manufacturing to meet global clinical and commercial regulatory standards. We remain committed to developing treatments for rare diseases and made significant advancements with our pipeline of treatments for diseases such as Batten, Duchenne, Hurler and Hunter Syndrome, the latter of which we expect will support a second BLA filing using the accelerated approval pathway. Our history, science, resources, people and values combine to make us an industry leader in gene therapy and in the development of potentially ground-breaking therapies. We look forward to providing additional updates about our progress in 2023."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on RGNX:

Related Articles
TipRanks Auto-Generated NewsdeskRegenXBio Appoints New EVP and CFO Amidst Key Developments
TheFlyRegenxbio names Mitchell Chan as CFO, succeeding Vit Vasista
TheFlyJMP Securities healthcare analysts hold an analyst/industry conference call
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App